MIMETAS B.V.

History

YearDetail
2013 Paul, Jos, and Bas founded MIMETAS in 2013 Leiden, the Netherlands.
2019 MIMETAS and Hubrecht Organoid Technology (HUB) collaborated to market organoid models on a Chip and develop disease-specific models.
2021 MIMETAS and Roche, a pharmaceutical company, collaborated to develop human disease models to characterize novel compounds in inflammatory bowel disease (IBD) and hepatitis B virus infections (HBV).
2023 The company partnered with Astellas Pharma Inc. to support the next generation of immuno-oncological therapies.
AI Sentiment